Pantop%2525252525252520ds

# Pantoprazole ## Overview Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the $H^+/K^+$-ATPase enzyme system at the secretory surface of the gastric parietal cell. It is available in oral (delayed-release tablets, suspension) and intravenous (IV) formulations. ## Primary Indications * Treatment of erosive esophagitis associated with GERD. * Maintenance of healing of erosive esophagitis. * Pathological hypersecretory conditions, including Zollinger-Ellison syndrome. * Short-term treatment of GERD-associated symptoms. ## Adult Dosing * **Erosive Esophagitis:** 40 mg orally or IV once daily for up to 8 weeks. Maintenance dose: 40 mg orally daily. * **GERD-associated symptoms:** 40 mg orally once daily for up to 4 weeks. * **Pathological Hypersecretory Conditions:** Starting dose 40 mg twice daily. Doses up to 240 mg daily have been administered. Adjust based on patient need; duration should be as long as clinically indicated. * **IV Administration:** Administer as a 15-minute infusion (at a rate of approx. 7 mL/min) or a 2-minute bolus (80 mL over 2 minutes). ## Pediatric Dosing * **GERD (5 years and older):** * 15 kg to <40 kg: 20 mg once daily for up to 8 weeks. * ≥40 kg: 40 mg once daily for up to 8 weeks. * Safety and efficacy in children <5 years have not been established. ## Dose Adjustments * **Hepatic Impairment:** No specific dose adjustment is required for mild to moderate impairment; however, consider reducing frequency in severe impairment (e.g., every other day), though labeling is conservative regarding specific limits. * **Renal Impairment:** No dosage adjustment necessary. * **Geriatric:** No dosage adjustment necessary. ## Contraindications * Known hypersensitivity to pantoprazole or any substituted benzimidazole (e.g., omeprazole, lansoprazole). * Concurrent use with rilpivirine-containing products. ## Adverse Effects * **Common:** Headache, diarrhea, nausea, abdominal pain, flatulence, injection site reactions (thrombophlebitis). * **Serious:** *Clostridioides difficile*-associated diarrhea (CDAD), bone fractures (long-term use), hypomagnesemia, vitamin B12 deficiency, acute interstitial nephritis, and cutaneous/systemic lupus erythematosus. ## Key Drug Interactions * **pH-Dependent Drugs:** May decrease absorption of agents such as atazanavir, nelfinavir, iron salts, and certain azole antifungals (e.g., ketoconazole). * **Methotrexate:** PPIs may increase serum levels of methotrexate, particularly in high-dose therapy. * **CYP2C19 Inhibitors/Inducers:** Though pantoprazole has a lower potential for drug-drug interactions compared to other PPIs, monitor for altered effects with strong CYP2C19 modulators. ## Monitoring * **Clinical:** Monitor for symptomatic improvement and signs of CDAD (persistent diarrhea). * **Labs:** Periodically monitor serum magnesium levels in patients on long-term therapy or those taking concomitant digoxin or diuretics. Monitor B12 levels if therapy exceeds 1-3 years. ## Clinical Pearls * **Administration:** Tablets should be swallowed whole; do not crush or chew. May be administered without regard to food. * **Discontinuation:** Sudden cessation may lead to "rebound acid hypersecretion." Tapering may be considered for long-term users. * **Stability:** IV pantoprazole solution should be clear and colorless. Once reconstituted, use within 24 hours. * **IV vs Oral:** IV pantoprazole is intended for short-term use when oral administration is not possible. Transition to oral therapy as soon as clinically feasible. *** *Disclaimer: This information is for educational purposes only. Clinical practice guidelines and drug labeling may change. Always consult the most current FDA-approved labeling, institutional formularies, and local prescribing protocols before making clinical decisions.*